Curapath

Spain (exact city not disclosed publicly)
Polymer Nanoparticles (PNP) Lipid Nanoparticles (LNP) PLGA/PLA Nanoparticles Polymer-Drug Conjugates Polymersomes Polymeric Micelles Polymer & Lipid Excipients Aseptic Fill & Finish
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (3) ○ EMA GMP ○ MHRA GMP

Quick Facts: Curapath

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Spain (exact city not disclosed publicly)
Modalities
Polymer Nanoparticles (PNP), Lipid Nanoparticles (LNP), PLGA/PLA Nanoparticles, Polymer-Drug Conjugates, Polymersomes, Polymeric Micelles, Polymer & Lipid Excipients, Aseptic Fill & Finish
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Curapath

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesPolymer Nanoparticles (PNP), Lipid Nanoparticles (LNP), PLGA/PLA Nanoparticles, Polymer-Drug Conjugates, Polymersomes, Polymeric Micelles, Polymer & Lipid Excipients, Aseptic Fill & Finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press3 articles
Broad modality coverage (8 modalities)

Recent News 3 articles

news Wed, 13 De
Curapath Appoints Philippe Clavel as Chief Executive Officer - citybiz
Source →
news Wed, 03 Se
Cayman Chemical and Curapath Partner to Provide Wider Access to PEG-Free Shielding Lipids for Lipid Nanoparticles - PR Newswire
Source →
news Mon, 15 De
Lipid Nanoparticles CDMO 2.0 Market Forecast with Size and Share Analysis 2025 to 2034 - Insightace Analytic
Source →

Frequently Asked Questions About Curapath

What is Curapath's CDMO Signal Score?
Curapath has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Curapath for a manufacturing program?
Use the free AI matchmaker to compare Curapath against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Lipid Nanoparticles (LNP) CDMOs → Polymer-Drug Conjugates CDMOs →